Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4779-4785

  Castanheira, Mariana ^a   Sader, Helio S ^a   Farrell, David J ^a,c   Mendes, Rodrigo E ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BACTERIAL ENZYME; BETA LACTAMASE; CEFTAROLINE; CEFTRIAXONE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; ENTEROBACTERIACEAE; GENE CASSETTE; GRAM NEGATIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CEPHALOSPORINS; CHROMOSOMES, BACTERIAL; DRUG COMBINATIONS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; ISOENZYMES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PLASMIDS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCAL INFECTIONS;

EID: 84865424472     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00817-12     Document Type: Article

References (19)

1. Biek D, Critchley IA, Riccobene TA, Thye DA. 2010. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J. Antimicrob. Chemother. 65(Suppl. 4): iv9-iv16.
2. Castanheira M, Farrell SE, Mendes RE, Jones RN. 2011. Contemporary (2010) diversity of β-lactamases among Enterobacteriaceae collected from bacteremias in U.S.A. hospitals: report from the SENTRY program, abstr. C2-1250. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 12-15, September 2011.
3. CTX-M among Enterobacteriaceae in U.S. medical centers: molecular evaluation from the MYSTIC Program (2007). Microb. Drug Resist. 14:211-216.
4. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY Antimicrobial Surveillance Programme (2007-09). J. Antimicrob. Chemother. 66:1409-1411.
5. Clinical and Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2012. M100-S22. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Corey GR, Wilcox MH, Talbot GH. 2010. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl. 4):iv41-iv51.
8. Critchley IA, et al. 2011. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J. Antimicrob. Chemother. 66(Suppl. 3):iii45-iii51.
9. Endimiani A, Choudhary Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producingKPCcarbapenemases. Antimicrob. Agents Chemother. 53:3599-3601.
10. EUCAST. 2011. European Committee on Antimicrobial Susceptibility Testing. 2012. Breakpoint tables for interpretation of MICs and zone diameters, version 2.0. EUCAST, Basel, Switzerland. http://www.eucast.org/clinical-breakpoints/. Accessed 1 January 2012.
11. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056.
12. Mendes RE, et al. 2010. Characterization of baseline methicillin- resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. J. Clin. Microbiol. 48:568-574.
13. Milheirico C, Oliveira DC, de Lencastre H. 2007. Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:3374-3377. (Pubitemid 350067556)
14. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. 2010. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1428-1432.
15. Perez-Perez FJ, Hanson ND. 2002. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40:2153-2162. (Pubitemid 34596400)
16. Rice LB. 2009. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12:476-481.
17. Stachyra T, et al. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329.
18. Wilcox MH, Corey GR, Talbot GH. 2010. CANVAS 2: the second phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65:iv53-iv65.
19. Woodford N, et al. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27:351-353.